METHOD OF DETERMINING THROMBOCYTE RESISTANCE TO DOUBLE ANTIPLATELET THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE Russian patent published in 2019 - IPC G01N33/49 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology, and can be used to determine resistance to double antiplatelet therapy in patients with ischemic heart disease. Method for determining platelet resistance to double antiplatelet therapy in patients with ischemic heart disease, receiving Cardiomagnyl (75 mg) and Clopidogrel (75 mg) for 6 months, consists in individual determination of light transmission values with graphic recording for 5 minutes with constant mixing and temperature of 37 °C, adding thrombocyte aggregation to the thrombocyte suspension at ratio of 10:1 one fold in concentration of 2 mcmole/l at 10 second of platelet aggregation registration on a laser aggregometer. Further, in addition to the platelet rich plasma, an inducer is introduced in ratio 2:1 2 mcmole/l at 1st, 2nd, 3rd and 4th minutes of the study, characterized by that the aggregation inducer used is adenosine diphosphate and when obtaining platelet aggregation values in range of 50 to 100 %, thrombocyte resistance to double antiplatelet therapy is determined.

EFFECT: this method reveals platelet resistance to double antiplatelet therapy (Cardiomagnyl and Clopidogrel) in patients with ischemic heart disease, which enables to optimize individual therapy.

1 cl, 3 ex